LIDDS (LIDDS.ST) Stock Analysis & AI Equity Report
LIDDS (LIDDS.ST) overview
LIDDS (LIDDS.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, LIDDS reported revenue of SEK 0.0m and operating profit of SEK -4.5m; the year-end share price was 0.10 SEK and market capitalisation was SEK 13.9m. LIDDS is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get LIDDS's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-03. Data will be refreshed during report generation.
About LIDDS
LIDDS AB (publ) is a Swedish biotechnology company focused on drug delivery and oncology. It develops NanoZolid, a proprietary platform for local, controlled release of medicines, and uses it in its own cancer pipeline and partner programs. The company also develops the NOV202 drug candidate and works with pharmaceutical partners on selected projects.
Generate the LIDDS report
LIDDS is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for LIDDS and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.